A retrospective global study of the prevalence of O-serotypes of invasive Escherichia coli disease in patients admitted to tertiary care hospitals.

IF 2.2 4区 医学 Q3 INFECTIOUS DISEASES
Jeroen Geurtsen, Joachim Doua, Luis Martinez-Martinez, Patricia Ibarra de Palacios, Jeff Powis, Matthew Sims, Peter Hermans, Olivier Barraud, Philippe Lanotte, Joshua Thaden, Oscar Go, Bart Spiessens, Darren Abbanat, Florian Wagenlehner, Tetsuya Matsumoto, Marc Bonten, Michal Sarnecki, Jan Poolman
{"title":"A retrospective global study of the prevalence of O-serotypes of invasive <i>Escherichia coli</i> disease in patients admitted to tertiary care hospitals.","authors":"Jeroen Geurtsen, Joachim Doua, Luis Martinez-Martinez, Patricia Ibarra de Palacios, Jeff Powis, Matthew Sims, Peter Hermans, Olivier Barraud, Philippe Lanotte, Joshua Thaden, Oscar Go, Bart Spiessens, Darren Abbanat, Florian Wagenlehner, Tetsuya Matsumoto, Marc Bonten, Michal Sarnecki, Jan Poolman","doi":"10.1017/S0950268825100344","DOIUrl":null,"url":null,"abstract":"<p><p>Invasive <i>Escherichia coli</i> disease (IED) is associated with high hospitalization and mortality rates, particularly among adults aged ≥60 years. O-antigens are virulence factors required for <i>E. coli</i> survival. To inform EXPEC9V development, a novel glycoconjugate vaccine targeting <i>E. coli</i> O-antigens that is no longer in active clinical development, this retrospective observational study describes O-serotype prevalence among <i>E. coli</i> isolates from IED patients. Eligible patients were identified from medical record databases (9 January 2018-8 November 2019) across 17 tertiary care hospitals in Europe, North America, and Asia. To estimate vaccine serotype coverage of EXPEC9V, <i>E. coli</i> isolates were O-serotyped using whole-genome sequencing and agglutination. Antimicrobial susceptibility testing was also performed. Nine hundred and two patients were enrolled, of whom 690 (76.5%) were aged ≥60 years. Common serotypes were O25, O2, O6, O1, O15, O75, O16, O4, and O18, with O25 being the most reported (17.3%). In patients aged ≥60 years, 422/637 <i>E. coli</i> isolates were EXPEC9V O-serotypes. EXPEC9V O-serotype prevalence did not substantially differ when stratified according to sex, presence of a positive blood culture, sepsis, fatality, or multidrug resistance. Consistent with previous studies, serotype O25 was most prevalent and associated with ~20% of cases. An EXPEC9V vaccine serotype coverage of 66.2% was observed for IED patients aged ≥60 years.</p>","PeriodicalId":11721,"journal":{"name":"Epidemiology and Infection","volume":" ","pages":"e109"},"PeriodicalIF":2.2000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epidemiology and Infection","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/S0950268825100344","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Invasive Escherichia coli disease (IED) is associated with high hospitalization and mortality rates, particularly among adults aged ≥60 years. O-antigens are virulence factors required for E. coli survival. To inform EXPEC9V development, a novel glycoconjugate vaccine targeting E. coli O-antigens that is no longer in active clinical development, this retrospective observational study describes O-serotype prevalence among E. coli isolates from IED patients. Eligible patients were identified from medical record databases (9 January 2018-8 November 2019) across 17 tertiary care hospitals in Europe, North America, and Asia. To estimate vaccine serotype coverage of EXPEC9V, E. coli isolates were O-serotyped using whole-genome sequencing and agglutination. Antimicrobial susceptibility testing was also performed. Nine hundred and two patients were enrolled, of whom 690 (76.5%) were aged ≥60 years. Common serotypes were O25, O2, O6, O1, O15, O75, O16, O4, and O18, with O25 being the most reported (17.3%). In patients aged ≥60 years, 422/637 E. coli isolates were EXPEC9V O-serotypes. EXPEC9V O-serotype prevalence did not substantially differ when stratified according to sex, presence of a positive blood culture, sepsis, fatality, or multidrug resistance. Consistent with previous studies, serotype O25 was most prevalent and associated with ~20% of cases. An EXPEC9V vaccine serotype coverage of 66.2% was observed for IED patients aged ≥60 years.

一项对三级医院住院患者侵袭性大肠杆菌o血清型患病率的全球回顾性研究
侵袭性大肠杆菌病(IED)与高住院率和死亡率相关,特别是在年龄≥60岁的成年人中。o抗原是大肠杆菌存活所需的毒力因子。为开发一种新的靶向大肠杆菌o型抗原的糖结合疫苗EXPEC9V,该疫苗已不再处于积极的临床开发阶段,本回顾性观察性研究描述了从IED患者分离的大肠杆菌中o型血清型的流行情况。从欧洲、北美和亚洲17家三级医疗医院的病历数据库(2018年1月9日至2019年11月8日)中确定了符合条件的患者。为了估计EXPEC9V疫苗血清型覆盖率,采用全基因组测序和凝集技术对大肠杆菌分离株进行o型血清分型。同时进行药敏试验。992例患者入组,其中690例(76.5%)年龄≥60岁。常见的血清型有O25、O2、O6、O1、O15、O75、O16、O4、O18,其中以O25型报告最多(17.3%)。在年龄≥60岁的患者中,422/637株大肠杆菌为EXPEC9V o血清型。当根据性别、阳性血培养、败血症、病死率或多药耐药进行分层时,EXPEC9V - o血清型患病率没有实质性差异。与以往的研究一致,血清型O25最为普遍,与约20%的病例相关。≥60岁IED患者的EXPEC9V疫苗血清型覆盖率为66.2%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Epidemiology and Infection
Epidemiology and Infection 医学-传染病学
CiteScore
4.10
自引率
2.40%
发文量
366
审稿时长
3-6 weeks
期刊介绍: Epidemiology & Infection publishes original reports and reviews on all aspects of infection in humans and animals. Particular emphasis is given to the epidemiology, prevention and control of infectious diseases. The scope covers the zoonoses, outbreaks, food hygiene, vaccine studies, statistics and the clinical, social and public-health aspects of infectious disease, as well as some tropical infections. It has become the key international periodical in which to find the latest reports on recently discovered infections and new technology. For those concerned with policy and planning for the control of infections, the papers on mathematical modelling of epidemics caused by historical, current and emergent infections are of particular value.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信